• Story Reviews
  • News Release Reviews
  • Blog
  • Podcasts
  • About Us
  • Toolkit for journalists and consumers
  • Contact
  • Newsletter Signup
HealthNewsReview.org HealthNewsReview.org HealthNewsReview.org
  • 2616 Story Reviews
  • 606 News Release Reviews
  • 2944 Blog Posts
  • Home
  • Story Reviews
  • News Release Reviews
  • Blog
  • Podcasts
  • About Us
    • Editorial Team
    • What We Review and How
    • Review Criteria
    • How Is the Star Score Determined?
    • Our Comments Policy
    • Accolades for HealthNewsReview.org
    • Talks, Workshops & Presentations
  • Toolkit
    • Tips for Analyzing Studies & Health Care Claims
    • Just for Journalists: Writing Tips
    • Stories of Patient Harm from Misleading Media
    • Pre-publication News Release Review
    • Health News Watchdog podcasts
    • News Sites & Blogs We Like
    • List of Industry-Independent Experts
    • Links to Other Resources
  • Contact

Search Results for "off-label"

5
9/7/2017

‘A blow to [STAT’s] credibility’: MD listed as author of op-ed praising drug reps didn’t write it. Ghostwriting/PR influence

[Editor’s note: In response to our reporting, STAT has retracted the flawed op-ed that is the subject of this post and revised its policies on authorship and conflict of interest disclosure in its opinion columns. See here for details.] The physician whom STAT lists as author of a now-retracted op-ed praising the vital role of […]

3
Conflicts of interest in healthcare
9/5/2017

Tone deaf again on pharma conflict of interest: STAT piece praising drug reps fails to disclose industry payments

[Editor’s note: The STAT article that’s the subject of this post has now been retracted following our investigation showing that the physician listed as the author did not write the piece, and that the content of the article was initially crafted with the assistance of a public relations firm.] I woke up this morning after a […]

5 star friday
5/12/2017

5-Star Friday: thoroughness & thoughtfulness

This is a unique Five Star Friday in that we have examples of great reporting from both the breaking news end of the spectrum, as well as a long-term and in-depth investigative project. We also have two stories that scored very highly with our reviewers. This is important because the two diseases covered — Alzheimer’s […]

May 10, 2017 | News Release Review

Data-mining expedition reports striking ketamine gold, but readers shouldn’t rush to judgment

A convoluted study and lack of cause and effect didn’t stop UCSD from making strong claims about ketamine.

2 Star
University of California - San Diego

First large-scale population analysis reinforces ketamine's reputation as antidepressant

May 8, 2017 | Story Review

A pat on the back to HealthDay for thorough report on ulcerative colitis drug

All it was missing was the cost of the drug.

5 Star
Health Day

Arthritis Drug Shows Promise for Ulcerative Colitis

April 20, 2017 | Story Review

CBS’s anecdotal story on botox for major depression omits major conflicts of interest

Relying on just one expert source invites trouble, particularly when the source has multiple ties to the intervention and stands to gain financially from its approval.

2 Star
CBSNews.com

Botox tested to help treat depression and social anxiety

April 11, 2017 | News Release Review

Allergan announcement on botox for depression obscures negative results

The trial didn’t hit its target of statistically significant benefit over placebo at 6 weeks.

2 Star
Allergan Plc

Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)

4
MS drug Ocrevus
4/3/2017

‘Fake breakthrough, fake news:’ One physician-researcher’s takeaway on news coverage of MS drug Ocrevus

The biggest health news of last week was undoubtedly the FDA approval of Roche’s Ocrevus for a severe form of multiple sclerosis. The New York Times, the Associated Press, CNN, NBC News, Fox News, STAT News, HealthDay, TIME.com, and Reuters–and many others–wrote about the drug, also known as ocrelizumab. When we peeked behind the headlines, though, we […]

5-Star Friday
3/3/2017

5-Star Friday • Informed patients & uninformed President? These journalists nail it!

It’s been a month since Punxsutawney Phil saw his shadow and I’m beginning to think it meant we were in for 6 weeks of great health care journalism (rather than 6 more weeks of winter). Last week was inspiring and this week had more excellent articles than we could write about. So don’t miss the links down at […]

February 1, 2017 | Story Review 1

Reuters Health provides balanced look at alternative remedies for premature ejaculation

The story made clear that there were limitations to the data, and that the placebo effect could have played a big role.

4 Star
Reuters Health

Alternative medicine might help treat premature ejaculation

12/12/2016

Ending journalism’s bad trip — why it’s important to communicate responsibly about the health effects of psychedelic drugs

We’ve seen some trippy coverage over the years when it comes to the health effects of psychedelic drugs. I’ll never forget Dr. Manny Alvarez’s Fox News interview with Chris Kilham, the self-proclaimed “Medicine Hunter,” who said he was swallowed by an anaconda while tripping on Amazonian ayahusca. That’s a hallucinatory brew which according to Kilham […]

11
12/6/2016

With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line  

The passage of the 21st Century Cures Act, which sailed through the House of Representatives last week on its way to a future White House signing ceremony, is due in no small measure to the activities of hundreds of patient advocacy groups and assorted other stakeholders that worked in overdrive the past two years pushing […]

November 30, 2016 | News Release Review

University release takes admirably cautious approach in describing leukemia treatment response

The release makes it abundantly clear that this is a small, preliminary trial result while providing a good description of benefits and an adequate overview of the trial.

4 Star
Washington University in St. Louis

In Highly Lethal Type of Leukemia, Cancer Gene Predicts Treatment Response

October 6, 2016 | Story Review 1

NY Times gives little scrutiny to industry-funded eczema drug studies

Patient anecdotes with extremely positive results throw the balance way off–along with the lack of independent opinions in a story weighted with drug industry sources.

3 Star
The New York Times

New Drug for Severe Eczema Is Successful in 2 New Trials

September 14, 2016 | News Release Review

Duke Health release earns applause for clear disclosure, but we wanted more info on harms and cost associated with this eye treatment

This news release earns praise for a very forthright disclosure, and solid reporting on the benefits and evidence, but it could have done more to inform readers about associated harms and the price tag for this expensive biologic drug.

4 Star
Duke Health

Humira Provides Effective, Non-Steroid Alternative for Eye Inflammation

  • « Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Toolkit

Tips & Resources for Analyzing Health Care Claims

Surrogate markers may not tell the whole story

Screening: How overdiagnosis and other harms can undermine the benefits

A place to tell stories of patient harm from misleading media

View More

Toolkit

Institutional Home

University of Minnesota - School of Public Health
  • Home
  • Story Reviews
  • News Release Reviews
  • Blog
  • About Us
  • Toolkit
  • Contact

Copyright © 2022 HealthNewsReview.org